Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07301697

Safety and Performance Profile of Cryobiopsy in Bronchial Endoscopy

Led by University Hospital, Strasbourg, France · Updated on 2026-01-15

30

Participants Needed

1

Research Sites

66 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Transbronchial cryobiopsy is a relatively recent technique, increasingly used for the diagnosis of various respiratory diseases, including neoplasms, diffuse interstitial lung diseases (ILDs), and rejection after lung transplantation. Currently, its use is included in European recommendations for the diagnosis of interstitial lung diseases. EBUS-cryobiopsy, on the other hand, has proven useful in the evaluation of lesions and mediastinal lymphadenopathy. Several studies have compared this method to the reference technique, EBUS-TBNA (endobronchial ultrasound-guided transbronchial needle aspiration), and the results suggest a higher diagnostic yield for cryobiopsy, particularly for detecting benign lesions and lymphomas. However, to date, no French recommendation has yet been published regarding the precise role of this examination in the management of mediastinal lesions. Since July 2024, transbronchial cryobiopsies and EBUS-cryobiopsies have been routinely performed in the thoracic endoscopy department of Strasbourg University Hospital by an experienced team of interventional pulmonologists. The indications are those described above, after approval in a multidisciplinary consultation meeting. The number of prospective studies on cryobiopsies is currently limited. With this study, the investigators aim to carry out work intended to complement the current data on the profitability and safety of using cryobiopsies in the center, based on their results obtained since July 2024, as well as through prospective data collection from procedures performed over a one-year period. In addition to a prospective component, this study has the strong point of evaluating the procedure conducted by a limited number of experienced operators, thereby reducing the risk of significant inter-operator variability, as has been observed in previous studies. Finally, this is the first French study on the subject. The investigators hypothesize that performing cryobiopsies in a large university hospital by experienced operators allows for obtaining satisfactory diagnostic results under good safety conditions.

CONDITIONS

Official Title

Safety and Performance Profile of Cryobiopsy in Bronchial Endoscopy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients who have undergone or are eligible for cryobiopsy according to national or international recommendations or after a failed first diagnostic test with collegial discussion
  • Procedure performed in the bronchial endoscopy department of Strasbourg University Hospitals
  • For diffuse interstitial lung diseases, decision for transbronchial cryobiopsy made after multidisciplinary consultation when diagnosis is unclear and surgical lung biopsy is not suitable or as an alternative
  • For lymph node puncture (EBUS-cryobiopsy), performed after multidisciplinary discussion as a second- or third-line procedure following diagnostic failure or as a first-line procedure alongside EBUS-TBNA if lymphoma is strongly suspected
  • For retrospective analysis, patients who underwent cryobiopsy or CT-guided lung biopsy since July 2024 for ILD diagnosis or suspected pulmonary neoplasm
Not Eligible

You will not qualify if you...

  • Patients under 18 years of age
  • Pregnant or breastfeeding women
  • Patients under guardianship, curatorship, or legal protection
  • Patients at increased bleeding risk: anticoagulants not stopped 24 hours prior, direct oral anticoagulants not stopped 5 days prior, INR > 1.5 for those on VKAs and heparin, dual antiplatelet therapy, platelet count below 50 G/L
  • Oxygen saturation below 90% on oxygen therapy with flow above 2 L/min
  • Severe heart disease including unstable angina, myocardial infarction, decompensated heart failure
  • Known pulmonary hypertension with systolic arterial pressure above 50 mmHg on echocardiography
  • Inability to provide informed consent due to emergency or comprehension difficulties

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Pulmonology Department - NHC Strasbourg

Strasbourg, France

Actively Recruiting

Loading map...

Research Team

M

Michele PORZIO, Doctor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here